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OR I G I N A L A R T I C L E

The role of conduct disorder in the relationship
between alcohol, nicotine and cannabis use disorders
J. D. Grant1*, M. T. Lynskey2, P. A. F. Madden1, E. C. Nelson1, L. R. Few1, K. K. Bucholz1,
D. J. Statham3, N. G. Martin4, A. C. Heath1 and A. Agrawal1
1

Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
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3
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4
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2

Background. Genetic inﬂuences contribute signiﬁcantly to co-morbidity between conduct disorder and substance use
disorders. Estimating the extent of overlap can assist in the development of phenotypes for genomic analyses.
Method. Multivariate quantitative genetic analyses were conducted using data from 9577 individuals, including 3982
complete twin pairs and 1613 individuals whose co-twin was not interviewed (aged 24–37 years) from two
Australian twin samples. Analyses examined the genetic correlation between alcohol dependence, nicotine dependence
and cannabis abuse/dependence and the extent to which the correlations were attributable to genetic inﬂuences shared
with conduct disorder.
Results. Additive genetic (a2 = 0.48–0.65) and non-shared environmental factors explained variance in substance use disorders. Familial effects on conduct disorder were due to additive genetic (a2 = 0.39) and shared environmental (c2 = 0.15)
factors. All substance use disorders were inﬂuenced by shared genetic factors (rg = 0.38–0.56), with all genetic overlap
between substances attributable to genetic inﬂuences shared with conduct disorder. Genes inﬂuencing individual substance use disorders were also signiﬁcant, explaining 40–73% of the genetic variance per substance.
Conclusions. Among substance users in this sample, the well-documented clinical co-morbidity between conduct disorder and substance use disorders is primarily attributable to shared genetic liability. Interventions targeted at generally
reducing deviant behaviors may address the risk posed by this shared genetic liability. However, there is also evidence
for genetic and environmental inﬂuences speciﬁc to each substance. The identiﬁcation of these substance-speciﬁc risk
factors (as well as potential protective factors) is critical to the future development of targeted treatment protocols.
Received 4 October 2014; Revised 16 July 2015; Accepted 17 July 2015; First published online 18 August 2015
Key words: Alcohol, cannabis, conduct disorder, genetic overlap, nicotine, substance use disorders, twins.

Introduction
There is substantial evidence that similar genetic factors inﬂuence liability to multiple substance use disorders (e.g. Kendler et al. 2003a, 2007; Rhee et al. 2006;
Young et al. 2006; Xian et al. 2008; Sartor et al. 2010;
Palmer et al. 2013). Most notably, Kendler et al. (2007)
identiﬁed two genetic factors, corresponding to the covariance across licit (alcohol, nicotine, caffeine) and illicit (cannabis, cocaine) drugs; however, the genetic
factors were highly correlated (r = 0.82). Conduct disorder has been repeatedly implicated as a co-morbid
feature of substance use disorders and there is substantial evidence that genetic inﬂuences contribute to this
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co-morbidity. For instance, another study by Kendler
and colleagues found that alcohol and drug dependence shared a sizeable proportion of their genetic liability with conduct and antisocial personality disorder,
and less so with internalizing disorders, such as depression (Kendler et al. 2003b). Button and colleagues
(2006) also found signiﬁcant genetic overlap between
conduct disorder and both alcohol and illicit drug dependence in an adolescent sample, and that residual
genetic overlap between alcohol and illicit drug dependence, after adjusting for conduct disorder, was
non-signiﬁcant. Similar results indicating the absence
of a residual genetic correlation between alcohol and
cannabis dependence when accounting for genetic
overlap with antisocial personality disorder have also
been noted in adult Vietnam era males (Fu et al.
2002). Other studies suggest that this shared liability
extends to additional aspects of externalizing behavior,
including novelty seeking and non-substance-related
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behavioral disinhibition (Krueger et al. 2002; Hicks
et al. 2011).
Based on this extant literature, it remains unanswered the extent to which the genetic covariation
across the three most common forms of substance
use disorder (i.e. alcohol, nicotine and cannabis) is attributable to genes shared with conduct disorder.
Two outcomes might be expected. One possibility is
that all the genetic inﬂuences on the three substances
are overlapping with each other and with conduct disorder, with limited evidence for substance-speciﬁc or
conduct disorder-speciﬁc genetic factors. This is unlikely given prior evidence for signiﬁcant substancespeciﬁc genetic inﬂuences on substance dependence
symptoms and on conduct disorder (Kendler et al.
2003b; Button et al. 2006, 2007). Alternatively, a moderate to high genetic correlation across the three substances might be expected, with evidence for
substance-speciﬁc genes. Whether the entire proportion of this genetic correlation is due to genes shared
with conduct disorder or whether some of this genetic
correlation is independent of it (i.e. shared across the
substances but not with conduct disorder) has not
been examined. This study of the extent to which the
genetics of conduct disorder contribute to genetic liability to substance use disorders is critical to
gene-ﬁnding efforts where increasing sample sizes,
often capitalizing on differing deﬁnitions of phenotypes with overlapping genetic underpinnings, is a necessity (Hicks et al. 2011). Equally important is the
estimation of substance-speciﬁc genetic inﬂuences.
For instance, Kendler et al. (2007) noted that substancespeciﬁc genetic variance ranged from 3% for cocaine to
91% for caffeine abuse/dependence symptoms.
To examine this question, we utilized data from 9577
adult male and female twins aged 24–37 years drawn
from two samples derived from the Australian Twin
Registry. Speciﬁcally we ﬁt a quadrivariate model
that examined the extent to which genetic and environmental inﬂuences were shared across conduct disorder
and DSM-IV diagnoses of nicotine dependence (ND)
and alcohol dependence (AD), and a modiﬁed cannabis abuse/dependence (CAD) diagnosis based on a
subset of DSM-IV criteria.

(Lynskey et al. 2012). The samples had comparable
ages at the time of interview (mean = 29.94 and mean =
31.85, respectively). After removing individuals of unknown zygosity and those with no data for any of the
four outcomes, the sample for the present analyses
included 9577 individuals (6255 of 6257 interviewed
individuals in the ﬁrst cohort; 3322 of 3348 interviewed individuals in the second cohort). The 3982
complete twin pairs included: 1096 monozygotic
(MZ, or identical) female twin pairs, 665 MZ male
pairs, 817 dizygotic (DZ, or fraternal) female pairs,
513 DZ male pairs, and 891 male–female twin pairs;
data from 1613 individuals without co-twin data,
which contribute to estimates of prevalence (but
not variance decomposition), were also included.
Zygosity was determined using standard items about
physical similarity which have been shown in a subset
of the present respondents to have 95% agreement
with DNA analysis (Medland et al. 2009). Verbal
informed consent was obtained from all participants,
and the procedures were approved by the Human
Research Protection Ofﬁce at Washington University
and the Human Research Ethics Committee at the
Queensland Institute of Medical Research.
Measures
Both cohorts completed a diagnostic telephone interview based on the Semi-structured Assessment of
the Genetics of Alcoholism [Australian version,
SSAGA-OZ (Bucholz et al. 1994; Heath et al. 1997)],
which included DSM-IV (APA, 1994) assessments of
conduct disorder, and ND, AD, and CAD.
Conduct disorder
Respondents were asked about 15 behaviors associated
with DSM-IV conduct disorder (e.g. bullying, threatening, stealing, rule-breaking). Individuals who indicated
that 53 behaviors (without requiring impairment) occurred within a 12-month period prior to age 18 years
were coded as having conduct disorder. None of the
items used in the conduct disorder section was related
to substance use or misuse.
Nicotine

Method and materials
Sample
Twin pairs from two cohorts of the volunteer
Australian Twin Registry were included in the present
analyses (Maciejewski et al. 2014). As described in detail elsewhere, telephone diagnostic interviews were
completed for one cohort in 1996–2000 (see Knopik
et al. 2004 for details) and for the other in 2005–2009

Respondents who had smoked at least 100 cigarettes
lifetime or who had smoked 21–99 cigarettes and had
smoked for at least 52 days a week for 53 weeks,
completed a detailed DSM-IV nicotine dependence
(ND) assessment. Individuals who endorsed 53 dependence symptoms (out of seven) within a
12-month period were coded as having a history of
ND. Because individuals who do not initiate using a
substance (i.e. never user) should be considered
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unmeasured for their liability to developing substance
use disorders (Neale et al. 2006), individuals who had
never tried cigarettes were coded as missing for ND
(n = 1001). Individuals with <3 dependence symptoms,
those whose symptoms did not cluster within a
12-month period, and individuals who had tried cigarettes but had only experimented with nicotine (i.e. had
smoked <100 cigarettes lifetime and had not smoked
for at least 52 days per week, n = 3900) were coded
as unaffected for ND.

Alcohol
Respondents were asked about their lifetime alcohol
consumption. Individuals who had consumed at least
ﬁve drinks in a 24-h period at least once completed a
detailed DSM-IV alcohol dependence (AD) assessment
and were included in analyses of AD. Those individuals who endorsed 53 AD symptoms (out of
seven) within a 12-month period were coded as having
a history of AD. Non-drinkers (n = 105) and those who
had not consumed at least ﬁve drinks in a 24-h period
(n = 908) were coded as missing for AD analyses.

Cannabis
Individuals who had used cannabis 511 times or who
had used cannabis at least monthly during the period
of heaviest use were asked questions tapping
DSM-IV cannabis abuse and dependence (CAD). The
ﬁrst cohort was only asked about two abuse symptoms
(hazardous use and role interference) and four dependence symptoms (tolerance, using more than intended,
continued use despite emotional/psychological problems caused/exacerbated by use, and repeated desire
or inability to cut down on use). Although the second
cohort was asked additional abuse and dependence
questions, the present analyses used only the symptoms assessed in both cohorts. Respondents were identiﬁed as having CAD if they endorsed any abuse
symptom or they endorsed 52 dependence symptoms
(symptoms were not required to have clustered within
a 12-month period). Because individuals who do not
initiate using a substance (i.e. never user) should be
considered unmeasured for their liability to developing substance use disorders (Neale et al. 2006), individuals who had never tried cannabis were coded as
missing for CAD (n = 3499). Individuals who completed the CAD section but did not meet the criteria
for CAD listed above as well as those who had minimal cannabis exposure (i.e. had tried cannabis but
used it <11 times and had not used it at least monthly
during their period of heaviest use; n = 3114) were
coded as unaffected for CAD.
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Statistical analyses
Quantitative genetic analyses were used to estimate the
relative contributions of genetic and environmental
factors to outcomes, and the overlap between diagnoses. As detailed elsewhere (Neale & Cardon, 1992),
twin models allow for the estimation of additive genetic factors (A), non-additive genetic factors (D), shared
environmental factors (C, environmental inﬂuences
that make twins similar to each other), and non-shared
environmental factors (E, environmental inﬂuences not
shared by twins, as well as error variance). Genetic
inﬂuences are indicated when the identical twin (MZ)
correlation is greater than the fraternal twin (DZ) correlation. If all twin pair similarity were attributable to
A, the MZ correlation would be about twice the DZ
correlation, because MZ twins share all of their genes
and DZ twins share half of their segregating genes
(on average). D is indicated when the DZ correlation
is less than half the MZ correlation (because MZ
twins again share all non-additive inﬂuences but DZ
twins only share one quarter of such inﬂuences, on
average), and C is indicated when the DZ correlation
is more than half the MZ correlation. Models containing only twins reared together cannot estimate both
C and D simultaneously, and a decision as to which
should be estimated is made based on correlations between identical and fraternal twins.
A quadrivariate Cholesky (lower triangular) decomposition was used to assess the degree of genetic and
environmental inﬂuence on each measure, as well as
the overlap across conduct disorder, ND, AD, and
CAD. A full Cholesky model allows for inﬂuences on
the ﬁrst variable to also load on all subsequent variables, and for novel inﬂuences on each subsequent
variable to load on all remaining variables. The E parameters in Fig. 1 show a full Cholesky parameterization,
and the comparable Cholesky parameterizations for
the familial components are shown in Supplementary
Fig. S1 [see also work by Neale and colleagues
(Neale & Cardon, 1992; Neale, 2004)]. Conduct disorder was entered into the Cholesky model ﬁrst.
Given that individuals become at risk for developing
dependence when they initiate substance use and
that not all users develop dependence, ordering of
the substance diagnosis variables in the Cholesky
model (ND, AD, CAD) was determined by the most
typical pattern of substance initiation. Of those who
had tried all three substances, 60.0% tried cigarettes before both alcohol and cannabis, and an additional
18.3% initiated multiple substances in the same year,
with cigarettes being one of those substances; 20.0%
initiated alcohol ﬁrst; 0.8% initiated cannabis ﬁrst. Of
individuals who had tried two of the three substances,
94.6% had used cigarettes and alcohol; 60.7% of those
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Fig. 1. Final quadrivariate genetic model with standardized parameter estimates. Paths are only shown for one twin; paths
for the second twin are equated to the ﬁrst twin, and connected to each other by ﬁxed values in keeping with quantitative
genetic theory (1.0 for genetic paths between MZ twins; 0.5 for genetic paths between DZ twins; 1.0 for shared environmental
paths between MZ and DZ twins). Latent variables are indicated by circles; observed variables by rectangles. A, Additive
genetic inﬂuences; C, shared environmental inﬂuences; E, non-shared environmental inﬂuences. The subscript 1 indicates
factors inﬂuencing conduct disorder; 2 is additional factors for nicotine dependence; 3 is additional factors for alcohol
dependence; 4 is additional factors for cannabis abuse/dependence; A1 is a genetic factor common to all measures. Diagonal
lines indicate paths from one measure that load on other measures. Solid lines indicate signiﬁcant paths. Parameter estimates
can be squared to determine the proportion of variance in the observed construct attributable to that path.

who had used two substances initiated cigarettes before alcohol, 21.1% initiated alcohol before cigarettes,
and 12.9% initiated cigarettes and alcohol within the
same year. This ordering of variables in the Cholesky
model (conduct disrder, ND, AD, CAD) was also supported by the mean ages of initiation (see Table 1).
The ﬁt of the full Cholesky model was compared to a
saturated model, which allowed us to test whether the
assumptions of twin modeling were met. Sub-models
dropping speciﬁc paths were used to test the signiﬁcance
of familial inﬂuences, and the overlap in inﬂuences across
measures. To minimize the large number of tests that
would need to be conducted to examine combinations
of paths that could be dropped from the model, omnibus
tests that constrained a family of paths were ﬁrst ﬁt to the
data in a manner that ﬁt with the correlation patterns and
with conceptually meaningful tests (single-parameter
tests, presented in Supplementary Table S2, conﬁrmed
that no individual path in an omnibus test was statistically signiﬁcant). The signiﬁcance of paths was tested by
comparing the ﬁt of each sub-model to the preceding
model and calculating the difference in −2 times the
log-likelihood of the prior model and the sub-model,

which is interpreted as a χ2 test for the given degrees
of freedom (df). Models were ﬁtted using the statistical package Mx (Neale, 2004) using full information maximum-likelihood estimation with raw data.
Analyzing raw data in Mx (Neale, 2004) allowed us to
utilize data from conduct disorder for everyone, and substance dependence data from each individual for the substances he/she had used more times than the cut-off
established. All quadrivariate models included gender
and cohort as covariates.
Ethical standards
The authors assert that all procedures contributing to
this work comply with the ethical standards of the relevant national and institutional committees on human
experimentation and with the Helsinki Declaration of
1975, as revised in 2008.
Results
Demographic and substance use characteristics are
shown in Table 1. Alcohol initiation was endorsed by
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Table 1. Demographic and substance use characteristics of 9577
members of Australian twin pairs aged 24–37 years
Years, mean (S.D.)
Mean age
Mean age
Mean age
Mean age
Mean age
Mean age
Mean age
Mean age

at
at
at
at
at
at
at
at

interview
conduct disorder onset
cigarette initiation
nicotine dependence onset
alcohol initiation
alcohol dependence onset
cannabis initiation
cannabis dependence onseta

30.60 (2.6)
13.84 (2.4)
14.06 (3.4)
21.96 (4.1)
15.83 (2.6)
21.87 (3.9)
18.50 (3.4)
21.36 (3.9)
No. (%)
3972 (41.5)
4102 (42.8)
1100 (11.6)

Male
Monozygotic
DSM-IV conduct disorder
Nicotine use and dependence
Ever smoked a cigarette
8470 (88.5)
DSM-IV nicotine dependence
Population prevalence
2770 (28.9)
Of ever smokers
2770 (32.7)
Alcohol use and dependence
Ever had a full drink of alcohol
9456 (98.9)
Ever had 55 drinks in a 24-h period
8544 (89.2)
DSM-IV alcohol dependence
Population prevalence
2219 (23.2)
Of those having consumed at least 5
2219 (26.0)
drinks in a 24 h period
Cannabis use and abuse/dependence
Ever used cannabis
6017 (63.2)
Cannabis abuse/dependence (modiﬁed DSM-IV)
Population prevalence
1683 (17.7)
Of ever users
1683 (28.0)
Data from n = 9577 individuals; n = 9501 individuals for
conduct disorder, n = 8470 for nicotine dependence, 8544 for
alcohol dependence, and n = 6017 for cannabis abuse/
dependence.
a
Age at clustering for n = 311 individuals in the second
cohort who met the modiﬁed DSM-IV cannabis abuse/
dependence diagnosis (CAD). The n = 1683 with CAD
included n = 1122 from the ﬁrst cohort (age at diagnosis not
assessed); of the n = 561 cohort 2 individuals with the
modiﬁed CAD diagnosis, age was not assessed for the n =
177 with abuse only or the n = 73 with the modiﬁed 52
symptom dependence diagnosis but not the full DSM-IV
dependence diagnosis with 53 symptoms and clustering.

almost 99% of the respondents, with 89% of the sample
reporting having consumed at least ﬁve drinks in a
24-h period and 26% of those having consumed 55
drinks in a 24-h period reporting a lifetime history of
AD. Over 88% of respondents had tried cigarettes,
with 33% of initiators having a history of ND.
Cannabis initiation was endorsed by 63% of respondents, with 28% of initiators having a history of
CAD. Mean age of onset of conduct disorder was
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13.84 years, which predated the average age of initiation for cigarettes (mean = 14.06), alcohol (mean =
15.83), and cannabis (mean = 18.50).
Because all univariate genetic analyses indicated that
the parameter estimates could be equated for men and
women [Δχ2(3) range: 2.30–6.38, all p > 0.05], quadrivariate analyses were collapsed across gender and gender was included as a covariate (see Supplementary
Table S1 for the correlations for all ﬁve zygosity
groups). MZ and DZ twin-pair correlations, tested
using SAS software version 9.2 (SAS Institute Inc.,
2002–2008), indicated signiﬁcant familiality for all
measures (see Table 2). Univariate genetic models
conﬁrmed that additive genetic inﬂuences and nonshared environmental inﬂuences were signiﬁcant for
all measures, with shared environmental inﬂuences
not reaching signiﬁcance for any measure, but reaching
p = 0.06 for conduct disorder (see Table 2).
A saturated model was used to estimate the tetrachoric correlations in Mx (Neale, 2004), and served as
a baseline from which to test the assumptions of the
genetic models (−2 times the log-likelihood = 31
827.135 with 72 estimated parameters). The initial
genetic model, which included additive genetic, shared
environmental, and non-shared environmental paths
in a Cholesky parameterization, indicated that the
Cholesky parameterization was reasonable for the current data (Δχ2 = 19.023, Δdf = 30, p = 0.94 compared to
the saturated model). Given that the correlation pattern
suggested genetic inﬂuence on all measures, with
smaller and less consistent evidence for shared environmental inﬂuences, we ﬁrst tested the signiﬁcance
of the shared environmental paths on and from ND
and AD. Eliminating all shared environmental
inﬂuences on and from ND (c21, c22, c32, and c42
in Supplementary Fig. S1) and AD (c31, c33, and c43
in Supplementary Fig. S1) resulted in a more parsimonious model without a signiﬁcant decrement in
ﬁt (total Δχ2 = 5.948, Δdf = 7, p = 0.55; also see
Supplementary Table S2 for the single-parameter
tests of change in model-ﬁt for this and all additional
tests). A test of the overlap in shared environmental
inﬂuences on conduct disorder and CAD indicated
that the overlap was not signiﬁcant (path c41 in
Supplementary Fig. S1; Δχ2 = −2.656, Δdf = 1, p > 0.99).
A sub-model specifying that all genetic overlap between the substances could be explained by genetic
inﬂuences shared with conduct disorder ﬁt the data
well (i.e. deleting paths a43, a42, and a32 from
Supplementary Fig. S1; Δχ2 = 0.664, Δdf = 3, p = 0.88;
also see Supplementary Table S2). From this model,
conﬁdence intervals and further model testing
conﬁrmed that it was possible to delete the remaining
CAD-speciﬁc shared environmental path (path c44 in
Supplementary Fig. S1; Δχ2 = 2.481, Δdf = 1, p = 0.12),
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Table 2. Twin-pair correlations and ﬁnal univariate genetic models (and 95% conﬁdence intervals) for conduct disorder, nicotine dependence,
alcohol dependence, and cannabis abuse/dependence

Conduct disorder
Nicotine dependence
Alcohol dependence
Cannabisabuse/dependence

rMZ

rDZ

A

C

E

0.55* (0.46–0.64)
0.63* (0.56–0.69)
0.51* (0.43–0.59)
0.63* (0.55–0.71)

0.39* (0.30–0.48)
0.31* (0.24–0.38)
0.22* (0.14–0.30)
0.40* (0.30–0.49)

0.32* (0.05–0.59)
0.62* (0.57–0.68)
0.47* (0.40–0.54)
0.63* (0.56–0.70)

0.20a (0.00–0.41)
–
–
–

0.48* (0.38–0.58)
0.38* (0.32–0.44)
0.53* (0.46–0.60)
0.37* (0.30–0.44)

A, Additive genetic inﬂuences; C, shared environmental inﬂuences; E, non-shared environmental inﬂuences.
Data from n = 9501 individuals for conduct disorder, n = 8470 for nicotine dependence, n = 8544 for alcohol dependence, and
n = 6017 for cannabis abuse/dependence.
*Signiﬁcant at p < 0.05;
a
Δχ2 = 3.59 when removed from the model, p = 0.06.

Table 3. Standardized proportions of variance (95% conﬁdence intervals) attributable to additive genetic, shared environmental, and
non-shared environmental inﬂuences in the best-ﬁtting quadrivariate model examining the genetic and environmental contributions to the
co-morbidity between conduct disorder, nicotine dependence, alcohol dependence, and cannabis abuse/dependence in 9577 Australian twins

Conduct disorder
Nicotine dependence
Alcohol dependence
Cannabis abuse/dependence

Additive genetic

Shared environment

0.39 (0.31–0.48)
0.62 (0.56–0.67)
0.48 (0.41–0.55)
0.65 (0.58–0.71)

0.15 (0.07–0.22)
–
–
–

Non-shared environment
0.46 (0.39–0.53)
0.38 (0.34–0.44)
0.52 (0.45–0.59)
0.35 (0.29–0.43)

All variance components signiﬁcant at p < 0.05.

but that all remaining genetic inﬂuences were statistically signiﬁcant, as indicated by a signiﬁcant decrement
in ﬁt when any path was deleted (Δχ2 range: 20.093–
262.394 with 1 df, all p < 0.001). Although modest in
magnitude, non-shared environmental inﬂuences overlapped across measures, with 5 of 6 paths being statistically signiﬁcant (Δχ2 range: 5.846–28.275 with 1 df, all
p < 0.005; the non-shared environmental path from conduct disorder to ND, which could be dropped without
a signiﬁcant decrement in ﬁt (Δχ2 = 0.169 with 1 df, all
p = 0.68), was retained in the ﬁnal model but is indicated by the dashed line in Fig. 1). The signiﬁcance
of the three substance-to-substance non-shared environmental parameters (e32, e42, and e43 from
Supplementary Fig. S1; also see Supplementary
Table S2) indicates that individual-speciﬁc effects
were shared across substances independent of the
effects each substance shared with conduct disorder.
The standardized parameter estimates from the
best-ﬁtting model are shown in Fig. 1, with the proportions of variance presented in Table 3 and the genetic
and environmental correlations in Table 4. As shown
in Table 3, familial inﬂuences accounted for substantial
variance in all measures, with genetic factors explaining 39% of the variance in conduct disorder, and
62%, 48%, and 65% of the variance in ND, AD, and

CAD, respectively. Shared environmental inﬂuences
accounted for an additional 15% of the variance in conduct disorder. Genetic correlations were signiﬁcant
and moderate to substantial (ranging from 0.38–0.77;
above the diagonal in Table 4), especially between conduct disorder and ND and CAD, where over 50% of
the genetic inﬂuences were overlapping. Importantly,
the genetic correlation across substances was entirely
attributable to genes shared with conduct disorder.
Non-shared environmental inﬂuences were predominantly measure speciﬁc, as shown by the modest correlations between individual-speciﬁc environmental
factors (range: 0.03–0.28; below the diagonal in
Table 4).
Discussion
In a large cohort of adult Australian twins, we show
that the previously well-documented shared genetic
etiology across ND, AD, and CAD was entirely attributable to genes contributed by a shared liability to conduct disorder. Our study extends previous research in
that we: (a) examined conduct disorder, ND, AD, and
CAD simultaneously in an adult sample [researchers
have examined these substances together (Kendler
et al. 2007, 2008), and have examined conduct disorder

Genetic overlap between conduct and substance use disorders
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Table 4. Genetic (above diagonal) and non-shared environmental correlationsa between conduct disorder, nicotine dependence, alcohol
dependence, and cannabis abuse/dependence from the best-ﬁtting model examining the genetic and environmental contributions to the
co-morbidity between conduct disorder, alcohol dependence, nicotine dependence and cannabis abuse/dependence in 9577 Australian twins

Conduct disorder
Nicotine dependence
Alcohol dependence
Cannabis abuse/dependence

Conduct disorder

Nicotine dependence

Alcohol dependence

Cannabis abuse/dependence

–
0.03 (−0.10 to 0.14)
0.28* (0.19 to 0.38)
0.17* (0.05 to 0.31)

0.77* (0.69–0.87 )
–
0.27* (0.17–0.35)
0.18* (0.06–0.31)

0.52* (0.44–0.61)
0.40* (0.33–0.48)
–
0.28* (0.17–0.39)

0.72* (0.64–0.81)
0.56* (0.48–0.64)
0.38* (0.31–0.45)
–

*Indicates p < 0.05.
Genetic correlations are above the diagonal; non-shared environmental correlations are below the diagonal.

a

with AD and general substance use disorders (Krueger
et al. 2002; Kendler et al. 2003b), but not all in the same
analysis]; (b) extended Hicks and colleagues analysis of
adolescents (aged 16–19 years; Hicks et al. 2011), which
could yield different patterns of overlap; (c) set to missing the data from individuals who had not initiated a
substance and hence had unknown genetic liability.
Our results are consistent with previous reports (Fu
et al. 2002; Kendler et al. 2003b; Button et al. 2006;
Hicks et al. 2011) showing that alcohol and drug dependence tend to share an appreciable proportion of
their genetic liability with conduct and antisocial personality disorder, and further demonstrating that similar effects extend to ND and to substance use disorders
contingent on initiation. The overall structure of genetic overlap (see Fig. 1) is also broadly consistent with
numerous twin studies of adolescent and adult populations indexing a general liability factor underlying a
host of externalizing disorders, including conduct disorder, substance use disorders and also impulsivity
and non-substance-related disinhibition (Krueger
et al. 2002; Hicks et al. 2011).
Such results have key implications for gene-ﬁnding
efforts such as genome-wide association studies
(GWAS). In particular, they imply that, as least when
examining initiators, phenotypes that aggregate across
various substance use disorders (e.g. Wetherill et al.
2015) or examine genetic variants that inﬂuence multiple substances (McGue et al. 2013; Vrieze et al. 2014)
may effectively be capturing genetic variation shared
with liability to conduct disorder. Thus, approaches
of aggregating across substances or of using conduct
disorder and other aspects of behavioral disinhibition
as proxies may be particularly useful in increasing
power to detect genetic variants shared across substances, particularly in adolescent cohorts where subjects may not have fully passed through the period of
greatest risk for onset of substance use disorders
(Iacono et al. 1999; Rose et al. 2004; Button et al. 2006;
Hicks et al. 2011). However, at least one study reports

that polygenic scores created for individual
substance-related measures and behavioral disinhibition are only modestly (r = 0.03–0.07) correlated with
each other (Vrieze et al. 2013).
Developmental changes in the degree to which genetic factors contribute to substance involvement itself
also should be considered, although there is disagreement about the pattern of change. For instance, research by Vrieze et al. (2012) suggests that the genetic
contribution to the overlap across substances may decline from adolescence into adulthood, while research
by Kendler and colleagues suggests that the genetic
contribution to overlap across substance use remains
steady, even increases modestly, across that time
span (Kendler et al. 2008). There is also evidence that
the correlation between conduct disorder and substance involvement is more attributable to shared environmental factors during adolescence (Rose et al.
2004). Thus, our ﬁnding of strong genetic overlap
may be speciﬁc to the age of our cohort (young adults)
and may not generalize to other developmental
settings.
Despite genetic overlap, the statistically signiﬁcant
role of substance-speciﬁc genetic inﬂuences cannot be
ignored. In fact, a signiﬁcant proportion of the genetic
variance in ND (40%), AD (73%), and CAD (47%) was
substance-speciﬁc. The ﬁnding of substance-speciﬁc
genetic inﬂuences corroborates previous research,
although the relatively higher proportion of speciﬁc
genetic inﬂuences on AD v. ND is in contrast to one
prior study that found ND to be most signiﬁcantly
inﬂuenced by speciﬁc genetic factors (Kendler et al.
2007). The magnitude of these speciﬁc genetic factors
underscores that when studying the genomic underpinnings of individual substance use disorders, variants are not exclusively expected to reﬂect a general
liability to conduct disorder or externalizing problems.
Most notably, for AD and ND, the most robustly validated single nucleotide polymorphisms identiﬁed via
GWAS have been substance speciﬁc. For alcohol,
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rs1229984 in the alcohol dehydrogenase (ADH1B) gene
is associated with accelerated conversion of ethanol to
acetaldehyde, thus protecting against alcoholism via a
speciﬁc metabolic pathway (Thomasson et al. 1993).
This functional polymorphism has been identiﬁed at
genome-wide signiﬁcant levels in two independent
studies (Bierut et al. 2012; Gelernter et al. 2014). For tobacco smoking, a similar metabolic variant in the cytochrome P450 A6 (CYP2A6) gene has been identiﬁed in
one large meta-analysis (Thorgeirsson et al. 2010).
However, the most widely replicated ﬁndings are for
tobacco smoking and rs16969968 in the cholinergic
nicotinic receptor α5 subunit (CHRNA5) (Liu et al.
2010; Thorgeirsson et al. 2010; Tobacco and Genetics
Consortium, 2010) and other variants in the family of
genes encoding nicotinic receptor subunits, which
have been repeatedly identiﬁed at genome-wide signiﬁcant levels. It is worth noting that the large GWAS
meta-analyses of smoking that identiﬁed rs16969968
relied on nicotine consumption measures such as cigarettes per day (not dependence) and primarily included
samples in which the co-morbid effects of conduct disorder are likely to be minimal. These substance-speciﬁc
ﬁndings have also arisen in a sample with a high degree of drug-related co-morbidity (e.g. Rice et al.
2012) but in that study, when studying one substance,
diagnoses of other substance use disorders were
accounted for, thus likely reﬁning the ability to home
in on substance-speciﬁc results. Future studies may
also wish to control for conduct disorder to further enhance chances of identifying drug-speciﬁc variants.
Some limitations of the current study are worth noting. First, this is a sample of adult Caucasian
Australians and ﬁndings may not generalize to other
ethnic groups. Second, in order to test for the role of
substance initiation on the genetic overlap with substance use disorder, we set to missing the substancespeciﬁc data for individuals who had never tried a
given substance (conduct disorder was analyzed for
everyone, as was substance dependence data from
each individual for the substances he/she had used
more times than the cutoff established). An alternate
approach would have been to use two-stage twin models where the relationship between substance use and
use disorders is expressly modeled (e.g. Kendler et al.
1999; Heath et al. 2002). However, this would have
resulted in a 7-variable multivariate structure which
our sample was underpowered to support. Third, a
related caveat is that we included nicotine and cannabis experimenters as unaffected for dependence; an alternative would have been to restrict the analyses to
those with more substantial exposure, as we did with
alcohol. It is possible that the genetic overlap of conduct disorder with ND and CAD might change with
a different substance use threshold (e.g. if conduct

disorder is associated more with the transition to ‘regular use’ than with the transition to ‘dependence’).
Fourth, the ordering of variables in our Cholesky
model reﬂects the most commonly reported order of
onset, but there are individuals who had a different
order of onset. Although our variance components
are applicable regardless of the order of onset, some
of the parameter estimates in the Cholesky model
would differ if a different variable order was used.
Fifth, there is some evidence that the genetic structure
of alcohol problems is not attributable to a single factor; in twin analyses examining the seven individual
symptoms of DSM-IV AD, Kendler et al. (2012) found
that the individual symptoms were best explained
using three distinct genetic factors. However, analyzing the individual symptoms for AD, ND and CAD
was beyond the scope of our analysis. Sixth, our
CAD diagnoses included only a subset of DSM-IV
symptoms (1+ of two abuse symptoms or 2+ of four dependence symptoms), which may have affected our
prevalence and/or heritability. This was done because
only this subset of items was included in the 1996–
2000 cohort assessment. However, Lynskey and colleagues (2002) have reported that a diagnosis of CAD
based on these six items reasonably approximates the
population prevalence and does not attenuate estimates of heritability. Finally, all of our diagnoses are
drawn from adult retrospective reports which may
have been subject to recall bias.
In this era of big data, several efforts are underway
to mega- and meta-analyze genome-wide data for substance use disorders. Our study indicates that looking
across substances may provide a unique set of genetic
variants that relate to a general vulnerability to conduct problems (at least among substance initiators),
whereas co-varying for co-morbid conduct disorder
may isolate substance speciﬁc ﬁndings. Importantly,
our study documents the enormous value of twin studies in providing a paradigm for development of
substance-related phenotypes for gene-identiﬁcation
efforts.
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